Education
About Us
Working with TipRanks
Follow Us
Protagenic Therapeutics, Inc. (PTIX)
:PTIX
RESEARCH TOOLSreports
PTIX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.35 - $15.53
Previous CloseN/A
Volume99.44K
Average Volume (3M)3.68M
Market Cap
$3.07M
Enterprise Value$22.67M
Total Cash (Recent Filing)$872.96K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-1.89
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-15.83
Shares Outstanding868,414
10 Day Avg. Volume182,939
30 Day Avg. Volume3,682,005
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)-36.56
Price to Sales (P/S)0.00
P/FCF Ratio-47.52
Enterprise Value/Market Cap7.37
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.00
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Protagenic Therapeutics News
PremiumCompany Announcements
Protagenic Therapeutics Announces Share Purchase Rights Distribution
PremiumCompany Announcements
Protagenic Therapeutics Secures $3.1M for Drug Development
PremiumCompany Announcements
Protagenic Therapeutics Issues Common Stock for Warrants
PremiumCompany Announcements
Protagenic Therapeutics Completes Acquisition of Phytanix Bio
Options Prices
Currently, No data available
---
Ownership Overview
6.29%
Insiders
4.98% Mutual Funds
0.24% Other Institutional Investors
94.76% Public Companies and
Individual Investors
PTIX FAQ
What was Protagenic Therapeutics, Inc.’s price range in the past 12 months?
Protagenic Therapeutics, Inc. lowest stock price was $2.35 and its highest was $15.53 in the past 12 months.
What is Protagenic Therapeutics, Inc.’s market cap?
Protagenic Therapeutics, Inc.’s market cap is $3.07M.
When is Protagenic Therapeutics, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Protagenic Therapeutics, Inc.’s earnings last quarter?
Protagenic Therapeutics, Inc. released its earnings results on Nov 16, 2021. The company reported -$2.8 earnings per share for the quarter, beating the consensus estimate of -$4.48 by $1.68.
Is Protagenic Therapeutics, Inc. overvalued?
According to Wall Street analysts Protagenic Therapeutics, Inc.’s price is currently Overvalued.
Does Protagenic Therapeutics, Inc. pay dividends?
Protagenic Therapeutics, Inc. does not currently pay dividends.
What is Protagenic Therapeutics, Inc.’s EPS estimate?
Protagenic Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Protagenic Therapeutics, Inc. have?
Protagenic Therapeutics, Inc. has 868,414 shares outstanding.
What happened to Protagenic Therapeutics, Inc.’s price movement after its last earnings report?
Protagenic Therapeutics, Inc. reported an EPS of -$2.8 in its last earnings report, beating expectations of -$4.48. Following the earnings report the stock price went down -2.874%.
Which hedge fund is a major shareholder of Protagenic Therapeutics, Inc.?
Currently, no hedge funds are holding shares in PTIX
Company Description
Protagenic Therapeutics, Inc.
Protagenic Therapeutics, Inc. (PTIX) is a biotechnology company operating in the pharmaceutical sector, with a focus on developing therapies for various central nervous system (CNS) disorders. The company's core product line includes proprietary neuropeptide-based therapeutics aimed at treating conditions such as depression, anxiety, post-traumatic stress disorder (PTSD), and other stress-related disorders. Protagenic Therapeutics leverages its intellectual property portfolio to advance its drug candidates through preclinical and clinical development stages.
Technical Analysis
ACADIA Pharmaceuticals
―
Brainstorm Cell Therapeutics
―
Anavex Life Sciences
―
Axsome Therapeutics
―
Annovis Bio
―